➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Colorcon
McKesson
Dow
McKinsey

Last Updated: November 30, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,039,780

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,039,780
Title:Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Inventor(s): Dutta; Panna (Fleminton, NJ), Rafai Far; Adel (Mount-Royal, CA), Ding; Min (Irvington, NY), Motheram; Rajeshwar (Dayton, NJ)
Assignee: Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:15/643,745
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,039,780
Patent Claims: 1. A method for treating, or reducing the risk of stent thrombosis or myocardial infarction, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical formulation comprising high purity cangrelor, or a salt thereof, as an active ingredient and one or more pharmaceutically acceptable excipients wherein the high purity cangrelor or salt thereof has a combined total of selected hydrolysis and oxidation degradants of cangrelor not exceeding about 1.5% by weight of the high purity cangrelor, and wherein the selected hydrolysis and oxidation degradants are one or more members selected from the group consisting of ##STR00003##

2. The method of claim 1, wherein the combined total of selected hydrolysis and oxidation degradants of cangrelor does not exceed about 1.3% by weight of the high purity cangrelor.

3. The method of claim 1, wherein the amount of impurity A is less than about 0.5% by weight, the amount of impurity B present is less than about 0.2% by weight, the amount of impurity C is less than about 0.3% by weight, the amount of impurity D is less than about 0.2% by weight, and the amount of impurity is less than about 0.5% by weight of the high purity cangrelor.

4. The method of claim 1, wherein the maximum impurity level of impurities A and D is each less than about 0.5% by weight of the high purity cangrelor.

5. The method of claim 1, wherein the pharmaceutically acceptable excipient is a polyol.

6. The method of claim 1, wherein the pharmaceutically acceptable excipients are mannitol and sorbitol.

7. A method for treating, or reducing the risk of stent thrombosis or myocardial infarction, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical formulation consisting of high purity cangrelor, or a salt thereof, as an active ingredient and mannitol and/or sorbitol as a pharmaceutically acceptable excipient wherein the high purity cangrelor or salt thereof has a combined total of selected hydrolysis and oxidation degradants of cangrelor not exceeding about 1.5% by weight of the high purity cangrelor, and wherein the selected hydrolysis and oxidation degradants are one or more members selected from the group consisting of ##STR00004##

8. The method of claim 7, wherein the combined total of selected hydrolysis and oxidation degradants of cangrelor does not exceed about 1.3% by weight of the high purity cangrelor.

9. The method of claim 7, wherein the amount of impurity A is less than about 0.5% by weight, the amount of impurity B present is less than about 0.2% by weight, the amount of impurity C is less than about 0.3% by weight, the amount of impurity D is less than about 0.2% by weight, and the amount of impurity E is less than about 0.5% by weight of the high purity cangrelor.

10. The method of claim 7, wherein the maximum impurity level of impurities A and D is each less than about 0.5% by weight of the high purity cangrelor.

11. A method for treating, or reducing the risk of stent thrombosis or myocardial infarction, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical formulation consisting of high purity cangrelor, or a salt thereof, as an active ingredient and mannitol and/or sorbitol as a pharmaceutically acceptable excipient wherein the high purity cangrelor or salt thereof has a combined total of selected hydrolysis and oxidation degradants of cangrelor not exceeding about 1.5% by weight of the high purity cangrelor, and wherein the selected hydrolysis and oxidation degradants are one or more members selected from the group consisting: ##STR00005##

12. The pharmaceutical formulation of claim 11, wherein the combined total of selected hydrolysis and oxidation degradants of cangrelor does not exceed about 1.3% by weight of the high purity cangrelor.

13. The method of claim 11, wherein the amount of impurity A is less than about 0.5% by weight, the amount of impurity B present is less than about 0.2% by weight, the amount of impurity C is less than about 0.3% by weight, the amount of impurity D is less than about 0.2% by weight, and the amount of impurity E is less than about 0.5% by weight of high purity the cangrelor.

14. The method of claim 1, wherein the pharmaceutical formulation comprises about 16-21% high purity cangrelor and about 84-79% of the one or more pharmaceutically acceptable excipients, by weight of the pharmaceutical formulation.

15. The method of claim 1, wherein the pharmaceutical formulation is administered to a subject via a parenteral mode of administration.

16. The method of claim 1, wherein the pharmaceutical formulation is administered to a subject via intravenous (IV) administration.

17. The method of claim 1, wherein the pharmaceutical formulation is administered to a subject via intravenous (IV) administration as a bolus, as a continuous infusion, or as a bolus followed by a continuous infusion.

18. The method of claim 7, wherein the pharmaceutical formulation is reconstituted into a sterile formulation and administered to a subject via a parenteral mode of administration.

19. The method of claim 7, wherein the pharmaceutical formulation is reconstituted into a sterile formulation and administered to a subject via intravenous (IV) administration.

20. The method of claim 7, wherein the pharmaceutical formulation is reconstituted into a sterile formulation and administered to a subject via intravenous (IV) administration as a bolus, as a continuous infusion, or as a bolus followed by a continuous infusion.

21. The method of claim 11, wherein the pharmaceutical formulation is reconstituted into a sterile formulation and administered to a subject via a parenteral mode of administration.

22. The method of claim 11, wherein the pharmaceutical formulation is reconstituted into a sterile formulation and administered to a subject via intravenous (IV) administration.

23. The method of claim 11, wherein the pharmaceutical formulation is reconstituted into a sterile formulation and administered to a subject via intravenous (IV) administration as a bolus, as a continuous infusion, or as a bolus followed by a continuous infusion.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Harvard Business School
Moodys
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.